A Phase 1/2 interventional study of AZP-3601 and Placebo in Chronic Hypoparathyroidism, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is investigating the safety, tolerability, pharmacodynamics and pharmacokinetics of AZP-3601 following single and repeated administration in both healthy volunteers and patients with chronic hypoparathyroidism (cHP)
The protocol includes 3 parts:
128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.
This study's enrollment of 132 is above the median of 50 across 77 interventional studies indexed under Hypoparathyroidism.
Browse Hypoparathyroidism studies →Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Main inclusion criteria
Part C:
Main exclusion criteria
Parts A and B:
Part C:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subcutaneous (sc) administration once daily
Drug: AZP-3601
subcutaneous (sc) administration once daily
Drug: Placebo
Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection
Also known as: eneboparatide
Saline solution visually matching active medication
Treatment Emergent Adverse Events (TEAEs)
Number of Treatment Emergent Adverse Events (TEAEs), as assessed by medDRA (v25).
Time frame: Up to 2 weeks in Part A and Part B, and up to 3 months in Part C
Observed Maximum Concentration (Cmax) - Part A
Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part A
Time frame: 24 hours
Observed Maximum Concentration (Cmax) - Part B
Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part B
Time frame: Day 1, Day 14
Observed Maximum Concentration (Cmax) - Part C
Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part C.
Time frame: Day 1, Day 14, Day 28, Day 84
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part A
Area under the plasma-drug concentration time curve (AUC) (pg\*h/mL) in Part A
Time frame: 24 hours
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part B
Area Under the Plasma-drug Concentration Time Curve (AUC) (pg\*h/mL) in Part B
Time frame: Day 1, Day 14
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part C
Area Under the Plasma-drug Concentration Time Curve (AUC) (pg\*h/mL) in Part C.
Time frame: Day 1, Day 14, Day 28, Day 84
Calcium Corrected for Albumin - Part A
Levels of calcium corrected for albumin (mg/dL) in Part A
Time frame: 24 hours
Calcium Corrected for Albumin - Part B
Levels of calcium corrected for albumin (mg/dL) in Part B
Time frame: 24 hours, Day 14
Calcium Corrected for Albumin - Part C
Levels of calcium corrected for albumin (mg/dL) in Part C.
Time frame: Day 1, Day 14, Day 28 and Day 84
Serum Phosphate - Part A
Serum phosphate levels (mg/dL) in Part A
Time frame: 24 hours
Serum Phosphate - Part B
Serum phosphate levels (mg/dL) in Part B
Time frame: Day 1, Day 14
Serum Phosphate - Part C
Serum phosphate levels (mg/dL) in Part C.
Time frame: Day 1 (H0), Day 14 (H2), Day 28 (H2) and Day 84 (H2)
Daily Dose of Oral Calcium and Active Vitamin D - Part C
Daily dose of oral calcium and active vitamin D for patients treated in Part C.
Time frame: Day 28 and Day 43
Calcium Excretion Rate 24h- Part C
24 hour calcium excretion rate (mg/24h) in Part C.
Time frame: Day 1, Day 14, Day 28 and Day 84
| Milestone | Part A (Cohort A1, 5 ug Dose) | Part A (Cohort A2, 10 ug Dose) | Part A (Cohort A3, 20 ug Dose) | Part A (Cohort A4, 40 ug Dose) | Part A (Cohort A5, 60 ug Dose) | Part A (Cohort A6, 120 ug Dose) | Part A (Cohort A7, 90 ug Dose) | Part A (Placebo) | Part B (Cohort B1, 10 ug Doses) | Part B (Cohort B2, 20 ug Doses) | Part B (Cohort B3, 40 ug Doses) | Part B (Cohort B4, 60 ug Doses) | Part B (Cohort B5, 80 ug Doses) | Part B (Placebo) | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 6 | 6 | 6 | 6 | 6 | 6 | 13 | 8 | 8 | 10 | 8 | 8 | 10 | 12 | 16 |
| Completed | 3 | 6 | 6 | 6 | 6 | 6 | 5 | 13 | 8 | 8 | 8 | 7 | 8 | 10 | 12 | 15 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
Number of Treatment Emergent Adverse Events (TEAEs), as assessed by medDRA (v25).
| Participants | Part A (Cohort A1, 5 ug Dose) | Part A (Cohort A2, 10 ug Dose) | Part A (Cohort A3, 20 ug Dose) | Part A (Cohort A4, 40 ug Dose) | Part A (Cohort A5, 60 ug Dose) | Part A (Cohort A6, 120 ug Dose) | Part A (Cohort A7, 90 ug Dose) | Part A (Placebo) | Part B (Cohort B1, 10 ug Doses) | Part B (Cohort B2, 20 ug Doses) | Part B (Cohort B3, 40 ug Doses) | Part B (Cohort B4, 60 ug Doses) | Part B (Cohort B5, 80 ug Doses) | Part B (Placebo) | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment Emergent Adverse Events (TEAEs) | 2 | 3 | 5 | 1 | 3 | 6 | 6 | 8 | 6 | 7 | 10 | 8 | 7 | 9 | 7 | 12 |
Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part A
| pg/mL | Part A (Cohort A1, 5 ug Dose) | Part A (Cohort A2, 10 ug Dose) | Part A (Cohort A3, 20 ug Dose) | Part A (Cohort A4, 40 ug Dose) | Part A (Cohort A5, 60 ug Dose) | Part A (Cohort A6, 120 ug Dose) | Part A (Cohort A7, 90 ug Dose) |
|---|---|---|---|---|---|---|---|
| Observed Maximum Concentration (Cmax) - Part A | 6.82 ± 2.19 | 11.4 ± 4.32 | 24.1 ± 8.18 | 26.3 ± 4.79 | 28.5 ± 10.8 | 57.4 ± 28.7 | 37.5 ± 11.6 |
Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part B
| pg/mL | Part B (Cohort B1, 10 ug Doses) | Part B (Cohort B2, 20 ug Doses) | Part B (Cohort B3, 40 ug Doses) | Part B (Cohort B4, 60 ug Doses) | Part B (Cohort B5, 80 ug Doses) |
|---|---|---|---|---|---|
| Day 1 | 20.6 ± 3.43 | 19.6 ± 5.68 | 23.8 ± 8.97 | 42.9 ± 30.3 | 124 ± 105 |
| Day 14 | 18.4 ± 5.37 | 18.3 ± 6.78 | 23.6 ± 5.50 | 44.9 ± 17.9 | 63.5 ± 28.3 |
Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part C.
| pg/mL | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) |
|---|---|---|
| Day 1 | 21.3 ± 9.20 | 11.9 ± 7.82 |
| Day 14 | 22.3 ± 11.7 | 10.4 ± 7.73 |
| Day 28 | 18.4 ± 7.42 | 21.5 ± 17.9 |
| Day 84 | — | 89.9 ± 63.9 |
Area under the plasma-drug concentration time curve (AUC) (pg\*h/mL) in Part A
| pg*h/mL | Part A (Cohort A1, 5 ug Dose) | Part A (Cohort A2, 10 ug Dose) | Part A (Cohort A3, 20 ug Dose) | Part A (Cohort A4, 40 ug Dose) | Part A (Cohort A5, 60 ug Dose) | Part A (Cohort A6, 120 ug Dose) | Part A (Cohort A7, 90 ug Dose) |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma-drug Concentration Time Curve (AUC) - Part A | 0.399 ± 0.032 | 5.20 ± 3.38 | 9.55 ± 4.12 | 10.4 ± 13.4 | 16.8 ± 14.7 | 26.1 ± 16.4 | 31.7 ± 12.5 |
Area Under the Plasma-drug Concentration Time Curve (AUC) (pg\*h/mL) in Part B
| pg*h/mL | Part B (Cohort B1, 10 ug Doses) | Part B (Cohort B2, 20 ug Doses) | Part B (Cohort B3, 40 ug Doses) | Part B (Cohort B4, 60 ug Doses) | Part B (Cohort B5, 80 ug Doses) |
|---|---|---|---|---|---|
| Day 1 | 3.26 ± 3.20 | 7.69 ± 5.52 | 15.8 ± 11.5 | 43.3 ± 18.1 | 64.2 ± 56.1 |
| Day 14 | 2.02 ± 2.41 | 4.63 ± 3.29 | 12.5 ± 4.75 | 58.8 ± 30.3 | 51.9 ± 51.6 |
Area Under the Plasma-drug Concentration Time Curve (AUC) (pg\*h/mL) in Part C.
| pg*h/mL | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) |
|---|---|---|
| Day 1 | 11.9 ± 9.53 | 4.90 ± 4.87 |
| Day 14 | 16.1 ± 14.0 | 3.99 ± 4.22 |
| Day 28 | 12.7 ± 7.58 | 11.8 ± 11.1 |
| Day 84 | — | 116 ± 111 |
Levels of calcium corrected for albumin (mg/dL) in Part A
| mg/dL | Part A (Cohort A1, 5 ug Dose) | Part A (Cohort A2, 10 ug Dose) | Part A (Cohort A3, 20 ug Dose) | Part A (Cohort A4, 40 ug Dose) | Part A (Cohort A5, 60 ug Dose) | Part A (Cohort A6, 120 ug Dose) | Part A (Cohort A7, 90 ug Dose) | Part A (Placebo) |
|---|---|---|---|---|---|---|---|---|
| Calcium Corrected for Albumin - Part A | 9.700 ± 0.0800 | 9.375 ± 0.6215 | 9.688 ± 0.3448 | 9.782 ± 0.4303 | 10.065 ± 0.2934 | 10.293 ± 0.5258 | 10.195 ± 0.2601 | 9.634 ± 0.3030 |
Levels of calcium corrected for albumin (mg/dL) in Part B
| mg/dL | Part B (Cohort B1, 10 ug Doses) | Part B (Cohort B2, 20 ug Doses) | Part B (Cohort B3, 40 ug Doses) | Part B (Cohort B4, 60 ug Doses) | Part B (Cohort B5, 80 ug Doses) | Part B (Placebo) |
|---|---|---|---|---|---|---|
| 24 hours | 9.818 ± 0.3283 | 9.661 ± 0.3492 | 10.121 ± 0.4320 | 10.01 ± 0.30 | 10.01 ± 0.41 | 9.68 ± 0.21 |
| Day 14 | 9.586 ± 0.3173 | 9.650 ± 0.2081 | 10.055 ± 0.5916 | 10.06 ± 0.59 | 10.94 ± 0.97 | 9.79 ± 0.24 |
Levels of calcium corrected for albumin (mg/dL) in Part C.
| mg/dL | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) |
|---|---|---|
| Day 1 (hour 0) | 8.44 ± 0.420 | 8.61 ± 0.552 |
| Day 14 | 8.48 ± 0.537 | 8.38 ± 0.726 |
| Day 28 | 8.64 ± 0.491 | 8.537 ± 0.697 |
| Day 84 | 7.95 ± 0.817 | 8.73 ± 0.878 |
Serum phosphate levels (mg/dL) in Part A
| mg/dL | Part A (Cohort A1, 5 ug Dose) | Part A (Cohort A2, 10 ug Dose) | Part A (Cohort A3, 20 ug Dose) | Part A (Cohort A4, 40 ug Dose) | Part A (Cohort A5, 60 ug Dose) | Part A (Cohort A6, 120 ug Dose) | Part A (Cohort A7, 90 ug Dose) | Part A (Placebo) |
|---|---|---|---|---|---|---|---|---|
| Serum Phosphate - Part A | 3.353 ± 0.6646 | 2.882 ± 0.3884 | 3.840 ± 0.5135 | 3.287 ± 0.5021 | 3.908 ± 0.5051 | 3.673 ± 0.4975 | 3.417 ± 0.4133 | 3.641 ± 0.3637 |
Serum phosphate levels (mg/dL) in Part B
| mg/dL | Part B (Cohort B1, 10 ug Doses) | Part B (Cohort B2, 20 ug Doses) | Part B (Cohort B3, 40 ug Doses) | Part B (Cohort B4, 60 ug Doses) | Part B (Cohort B5, 80 ug Doses) | Part B (Placebo) |
|---|---|---|---|---|---|---|
| Day 1 | 3.616 ± 0.1919 | 3.751 ± 0.3229 | 3.824 ± 0.5421 | 3.518 ± 0.3332 | 3.398 ± 0.3965 | 3.65 ± 0.58 |
| Day 14 | 3.601 ± 0.2299 | 3.850 ± 0.3397 | 3.603 ± 0.4738 | 3.727 ± 0.3970 | 3.553 ± 0.6037 | 3.74 ± 0.40 |
Serum phosphate levels (mg/dL) in Part C.
| mg/dL | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) |
|---|---|---|
| Day 1 | 4.12 ± 0.798 | 4.53 ± 0.780 |
| Day 14 | 3.43 ± 0.742 | 3.95 ± 0.849 |
| Day 28 | 3.50 ± 0.843 | 3.82 ± 0.868 |
| Day 84 | 3.60 ± 0.589 | 3.80 ± 6.83 |
Daily dose of oral calcium and active vitamin D for patients treated in Part C.
| Participants | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) |
|---|---|---|
| Number of patients taking =< 500 mg/day of calcium on Day 28 | 9 | 12 |
| Number of patients taking =< 500 mg/day of calcium on Day 84 | 8 | 13 |
| Number of patients taking no vitamin D on Day 28 | 10 | 12 |
| Number of patients taking no vitamin D on Day 84 | 9 | 13 |
24 hour calcium excretion rate (mg/24h) in Part C.
| mg/24h | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) |
|---|---|---|
| Day 1 | 328.72 ± 130.950 | 330.73 ± 189.154 |
| Day 14 | 224.83 ± 108.570 | 188.41 ± 100.054 |
| Day 28 | 155.06 ± 61.705 | 166.43 ± 96.637 |
| Day 84 | 115.70 ± 37.929 | 145.15 ± 113.563 |
Collected over Up to 2 weeks (Part A and Part B) and up to 3 months (Part C). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A (Cohort A1, 5 ug Dose) | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part A (Cohort A2, 10 ug Dose) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part A (Cohort A3, 20 ug Dose) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part A (Cohort A4, 40 ug Dose) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A (Cohort A5, 60 ug Dose) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part A (Cohort A6, 120 ug Dose) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part A (Cohort A7, 90 ug Dose) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part A (Placebo) | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) |
| Part B (Cohort B1, 10 ug Doses) | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Part B (Cohort B2, 20 ug Doses) | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Part B (Cohort B3, 40 ug Doses) | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Part B (Cohort B4, 60 ug Doses) | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Part B (Cohort B5, 80 ug Doses) | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Part B (Placebo) | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Part C (Cohort C1, Starting Dose of 20 ug/Day) | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Part C (Cohort C2, Starting Dose of 10 ug/Day) | 0/16 (0%) | 0/16 (0%) | 12/16 (75%) |
| Event | Part A (Cohort A1, 5 ug Dose) | Part A (Cohort A2, 10 ug Dose) | Part A (Cohort A3, 20 ug Dose) | Part A (Cohort A4, 40 ug Dose) | Part A (Cohort A5, 60 ug Dose) | Part A (Cohort A6, 120 ug Dose) | Part A (Cohort A7, 90 ug Dose) | Part A (Placebo) | Part B (Cohort B1, 10 ug Doses) | Part B (Cohort B2, 20 ug Doses) | Part B (Cohort B3, 40 ug Doses) | Part B (Cohort B4, 60 ug Doses) | Part B (Cohort B5, 80 ug Doses) | Part B (Placebo) | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/3 | 0/6 | 0/6 | 0/6 | 1/6 | 4/6 | 3/6 | 1/13 | 0/8 | 2/8 | 1/10 | 5/8 | 4/8 | 3/10 | 1/12 | 0/16 |
| SomnolenceNervous system disorders | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 4/6 | 1/6 | 0/13 | 0/8 | 0/8 | 3/10 | 3/8 | 2/8 | 1/10 | 0/12 | 0/16 |
| Injection Site HematomaGeneral disorders | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/13 | 2/8 | 3/8 | 5/10 | 3/8 | 3/8 | 3/10 | 1/12 | 2/16 |
| Decreased appetiteMetabolism and nutrition disorders | 0/3 | 0/6 | 1/6 | 0/6 | 0/6 | 3/6 | 2/6 | 0/13 | 0/8 | 0/8 | 1/10 | 2/8 | 0/8 | 0/10 | 0/12 | 0/16 |
| headacheNervous system disorders | 1/3 | 1/6 | 1/6 | 0/6 | 0/6 | 3/6 | 2/6 | 0/13 | 0/8 | 1/8 | 2/10 | 4/8 | 1/8 | 3/10 | 2/12 | 4/16 |
| Injection Site ErythemaGeneral disorders | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 1/13 | 0/8 | 1/8 | 4/10 | 3/8 | 2/8 | 1/10 | 1/12 | 5/16 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/3 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/13 | 1/8 | 0/8 | 4/10 | 0/8 | 0/8 | 0/10 | 0/12 | 0/16 |
| VomitingGastrointestinal disorders | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/13 | 0/8 | 0/8 | 0/10 | 3/8 | 1/8 | 0/10 | 0/12 | 0/16 |
| Vessel puncture site hematomaGeneral disorders | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/13 | 0/8 | 3/8 | 0/10 | 1/8 | 1/8 | 2/10 | 0/12 | 0/16 |
| Injection Site PainGeneral disorders | 0/3 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 2/6 | 4/13 | 1/8 | 0/8 | 0/10 | 2/8 | 1/8 | 1/10 | 1/12 | 0/16 |
| Age, Continuous(years) | Part A (Cohort A1, 5 ug Dose) | Part A (Cohort A2, 10 ug Dose) | Part A (Cohort A3, 20 ug Dose) | Part A (Cohort A4, 40 ug Dose) | Part A (Cohort A5, 60 ug Dose) | Part A (Cohort A6, 120 ug Dose) | Part A (Cohort A7, 90 ug Dose) | Part A (Placebo) | Part B (Cohort B1, 10 ug Doses) | Part B (Cohort B2, 20 ug Doses) | Part B (Cohort B3, 40 ug Doses) | Part B (Cohort B4, 60 ug Doses) | Part B (Cohort B5, 80 ug Doses) | Part B (Placebo) | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 29.3 (28 to 30) | 38.8 (20 to 59) | 23.7 (19 to 33) | 30.0 (20 to 60) | 26.3 (20 to 50) | 21.0 (18 to 24) | 35.3 (23 to 58) | 29.2 (18 to 57) | 38.3 (19 to 59) | 42.9 (28 to 60) | 39.7 (19 to 59) | 30.1 (19 to 43) | 33.3 (20 to 48) | 32.0 (22 to 57) | 62.7 (44 to 72) | 54.0 (26 to 72) | 37.9 (18 to 72) |
| Sex: Female, Male(Participants) | Part A (Cohort A1, 5 ug Dose) | Part A (Cohort A2, 10 ug Dose) | Part A (Cohort A3, 20 ug Dose) | Part A (Cohort A4, 40 ug Dose) | Part A (Cohort A5, 60 ug Dose) | Part A (Cohort A6, 120 ug Dose) | Part A (Cohort A7, 90 ug Dose) | Part A (Placebo) | Part B (Cohort B1, 10 ug Doses) | Part B (Cohort B2, 20 ug Doses) | Part B (Cohort B3, 40 ug Doses) | Part B (Cohort B4, 60 ug Doses) | Part B (Cohort B5, 80 ug Doses) | Part B (Placebo) | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 9 | 12 | 25 |
| Male | 3 | 6 | 6 | 6 | 6 | 6 | 6 | 13 | 8 | 6 | 9 | 8 | 8 | 9 | 3 | 4 | 107 |
| Ethnicity (NIH/OMB)(Participants) | Part A (Cohort A1, 5 ug Dose) | Part A (Cohort A2, 10 ug Dose) | Part A (Cohort A3, 20 ug Dose) | Part A (Cohort A4, 40 ug Dose) | Part A (Cohort A5, 60 ug Dose) | Part A (Cohort A6, 120 ug Dose) | Part A (Cohort A7, 90 ug Dose) | Part A (Placebo) | Part B (Cohort B1, 10 ug Doses) | Part B (Cohort B2, 20 ug Doses) | Part B (Cohort B3, 40 ug Doses) | Part B (Cohort B4, 60 ug Doses) | Part B (Cohort B5, 80 ug Doses) | Part B (Placebo) | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 3 | 0 | 0 | 9 |
| Not Hispanic or Latino | 3 | 6 | 6 | 6 | 6 | 5 | 6 | 12 | 8 | 8 | 9 | 7 | 6 | 7 | 12 | 15 | 122 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Part A (Cohort A1, 5 ug Dose) | Part A (Cohort A2, 10 ug Dose) | Part A (Cohort A3, 20 ug Dose) | Part A (Cohort A4, 40 ug Dose) | Part A (Cohort A5, 60 ug Dose) | Part A (Cohort A6, 120 ug Dose) | Part A (Cohort A7, 90 ug Dose) | Part A (Placebo) | Part B (Cohort B1, 10 ug Doses) | Part B (Cohort B2, 20 ug Doses) | Part B (Cohort B3, 40 ug Doses) | Part B (Cohort B4, 60 ug Doses) | Part B (Cohort B5, 80 ug Doses) | Part B (Placebo) | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 |
| White | 3 | 5 | 5 | 5 | 5 | 5 | 6 | 10 | 8 | 5 | 10 | 7 | 3 | 7 | 12 | 16 | 112 |
| More than one race | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 3 | 0 | 1 | 0 | 0 | 2 | 2 | 0 | 0 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part A (Cohort A1, 5 ug Dose) | Part A (Cohort A2, 10 ug Dose) | Part A (Cohort A3, 20 ug Dose) | Part A (Cohort A4, 40 ug Dose) | Part A (Cohort A5, 60 ug Dose) | Part A (Cohort A6, 120 ug Dose) | Part A (Cohort A7, 90 ug Dose) | Part A (Placebo) | Part B (Cohort B1, 10 ug Doses) | Part B (Cohort B2, 20 ug Doses) | Part B (Cohort B3, 40 ug Doses) | Part B (Cohort B4, 60 ug Doses) | Part B (Cohort B5, 80 ug Doses) | Part B (Placebo) | Part C (Cohort C1, Starting Dose of 20 ug/Day) | Part C (Cohort C2, Starting Dose of 10 ug/Day) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hungary | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 6 | 15 |
| Spain | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 7 |
| France | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 |
| Netherlands | 3 | 6 | 6 | 6 | 6 | 6 | 6 | 13 | 8 | 8 | 10 | 8 | 8 | 10 | 0 | 0 | 104 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2020 to primary completion in Aug 2022, 23 months.
Results were first posted in Jan 2024, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alexion Pharmaceuticals, Inc. →